Henogen's strategic decision to complement its CMO activities with the development of proprietary products required the identification of a line of products consistent with the expertise, the size and the production capacity of the company. These conditions oriented the choice towards products having niche as mid-size markets and corresponding to strong medical needs, suitable for therapeutical indications where no other or only suboptimal cures were available. In addition, the products of choice had not only to generate high added value for the niche (mid-size) market indications but also, if possible, have the strong potential for licensing out additional therapeutical indications addressing much larger markets. On these basis, Henogen decided to enter the Transplantation field as main target. The focus was placed on the protection of transplant patients, either through induction of immune tolerance after grafting or by prevention of viral associated malignancies pre or post-transplantation. In this respect, Henogen's goal is to develop, produce, test clinically and market, or out-license, specific product combinations (adjuvanted or conjugated active ingredients) together with specific administration regimens. AWEX